Affordable Access

Publisher Website

Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection.

  • Malczewska, Anna1, 2
  • Frampton, Adam E1
  • Mato Prado, Mireia1
  • Ameri, Shima1
  • Dabrowska, Aleksandra F1
  • Zagorac, Sladjana1
  • Clift, Ashley K1
  • Kos-Kudła, Beata2
  • Faiz, Omar3
  • Stebbing, Justin1
  • Castellano, Leandro1, 4
  • Frilling, Andrea1
  • 1 Department of Surgery & Cancer, Imperial College, Hammersmith Hospital campus, Du Cane Road, London, UK.
  • 2 Department of Endocrinology and Neuroendocrine Tumors, Medical University of Silesia, Katowice, Poland. , (Poland)
  • 3 St. Mark's Hospital, Harrow, Middlesex, UK.
  • 4 University of Sussex, School of Life Sciences, John Maynard Smith Building, Falmer, Brighton, UK.
Published Article
Annals of surgery
Publication Date
Jul 01, 2021
DOI: 10.1097/SLA.0000000000003502
PMID: 31373926


To discover serum-based microRNA (miRNA) biomarkers for small-bowel neuroendocrine tumors (SBNET) to help guide clinical decisions. MiRNAs are small noncoding RNA molecules implicated in the initiation and progression of many cancers. MiRNAs are remarkably stable in bodily fluids, and can potentially be translated into clinically useful biomarkers. Novel biomarkers are needed in SBNET to determine disease aggressiveness, select patients for treatment, detect early recurrence, and monitor response. This study was performed in 3 stages (discovery, validation, and a prospective, longitudinal assessment). Discovery comprised of global profiling of 376 miRNA in sera from SBNET patients (n = 11) versus healthy controls (HCs; n = 3). Up-regulated miRNAs were subsequently validated in additional SBNET (n = 33) and HC sera (n = 14); and then longitudinally after SBNET resection (n = 12), with serial serum sampling (preoperatively day 0; postoperatively at 1 week, 1 month, and 12 months). Four serum miRNAs (miR-125b-5p, -362-5p, -425-5p and -500a-5p) were significantly up-regulated in SBNET (P < 0.05; fold-change >2) based on multiple normalization strategies, and were validated by RT-qPCR. This combination was able to differentiate SBNET from HC with an area under the curve of 0.951. Longitudinal assessment revealed that miR-125b-5p returned towards HC levels at 1 month postoperatively in patients without disease, whereas remaining up-regulated in those with residual disease (RSD). This was also true at 12 months postoperatively. In addition, miR-362-5p appeared up-regulated at 12 months in RSD and recurrent disease (RCD). Our study represents the largest global profiling of serum miRNAs in SBNET patients, and the first to evaluate ongoing serum miRNA expression changes after surgical resection. Serum miR-125b-5p and miR-362-5p have potential to be used to detect RSD/RCD. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Report this publication


Seen <100 times